Cargando…
Monoclonal Antibodies Against Human Papillomavirus E6 and E7 Oncoproteins Inhibit Tumor Growth in Experimental Cervical Cancer
Nearly all cases of cervical cancer are initiated by persistent infection with high-risk strains of human papillomavirus (hr-HPV). When hr-HPV integrates into the host genome, the constitutive expression of oncogenic HPV proteins E6 and E7 function to disrupt p53 and retinoblastoma regulation of cel...
Autores principales: | Jiang, Zewei, Albanese, Joseph, Kesterson, Joshua, Warrick, Joshua, Karabakhtsian, Rouzan, Dadachova, Ekaterina, Phaëton, Rébécca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6642219/ https://www.ncbi.nlm.nih.gov/pubmed/31325765 http://dx.doi.org/10.1016/j.tranon.2019.06.003 |
Ejemplares similares
-
Combined treatment of the experimental human papilloma virus-16-positive cervical and head and neck cancers with cisplatin and radioimmunotherapy targeting viral E6 oncoprotein
por: Harris, M, et al.
Publicado: (2013) -
Beta emitters rhenium‐188 and lutetium‐177 are equally effective in radioimmunotherapy of HPV‐positive experimental cervical cancer
por: Phaeton, Rebecca, et al.
Publicado: (2015) -
Modulation of DNA methylation by human papillomavirus E6 and E7 oncoproteins in cervical cancer
por: Sen, Prakriti, et al.
Publicado: (2018) -
Immunohistochemical Detection of Human Papillomavirus 16 E7 Oncoprotein in Cervical Lesions
por: Zhu, Jiang, et al.
Publicado: (2021) -
Golgi Alkalinization by the Papillomavirus E5 Oncoprotein
por: Schapiro, Florencia, et al.
Publicado: (2000)